Navigation Links
Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
Date:5/18/2009

San Francisco, CA May 18, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

"A significant number of pediatric ADHD patients present with behaviors such as anger, resentfulness, defiance, and arguing with adults. It can be complicated for physicians and caregivers to find the right medication to control symptoms for children with ADHD exhibiting these behaviors," said Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with the primary efficacy results of the current study, these data provide additional support for the clinical efficacy of INTUNIV for treating ADHD in this patient population."

On January 26, 2009, Shire filed a resubmission to the US Food and Drug Administration (FDA) of the New Drug Application to support approval for the treatment of ADHD in children and adolescents. Once available, INTUNIV will be the first selective alpha-2A receptor agonist approved for the treatment of ADHD.

INTUNIV Demonstrated Significant Efficacy in Secondary Endpoints

In this randomized, placebo-controlled, flexible-dose study, INTUNIV demonstrated significant ADHD symptom improvement in patients with oppositional symptoms as measured by the ADHD Rating Scale-IV (ADHD-RS-IV), a scale frequently used in ADHD clinical trials. In results from this study presented today, INTUNIV also demonstrated sy
'/>"/>

Contact: Debra Gemme
debra.gemme@porternovelli.com
212-601-8342
Porter Novelli
Source:Eurekalert

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
2. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
3. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
4. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
5. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
6. Cipher receives tentative FDA approval for extended-release tramadol capsules
7. Bioniche Warrants Expiration Date to be Extended
8. Teaching Hospitals Post-Op Gains Not Extended to Blacks
9. Stroke therapy window might be extended past nine hours for some
10. Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio
11. Get Screened Video Contest Deadline Extended to Jan. 30

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...tailing plastic surgery procedures is now availabl...dates can view procedures and print out informatio... (PRWEB) December 2, 2009 -- Recovery..., has always been dedicated to providing resources...es, providing liposuction garments, breast augment...
(Date:12/2/2009)...uthor James A. Feinstein, MD, has just released hi...s from Patients on Becoming a Doctor, that traces ...hool--the grueling clinical year. , ...009 -- Most people will, at some point or another,... gown or staring at someone else dressed in a tiny...
(Date:12/2/2009)...e-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: G...y Health Care Conference today at 2:30 p.m. Easter...t live and may be accessed through a link on the i...n-probe.com . The webcast will be available for 30... ,, Gen-Probe Incorporated is a global leader ...
(Date:12/2/2009)...wire/ -- LeapFrog Investments has announced a ZAR ...fe, the innovative South African insurer serving p... brings together LeapFrog, the leading microinsura...most innovative insurance businesses. The announce...fe has developed a distinctive and profitable busi...
(Date:12/2/2009)...cal trial presented today at the annual meeting of...provide the first strong evidence of the benefit o... breasts who are at elevated risk for breast cance...ghly sensitive in depicting early breast cancer. ,... in addition to mammography significantly improves...
Breaking Medicine News(10 mins):Health News:Online Compression Garments Retailer Introduces 3D Animation of Surgical Procedures 2Health News:Beneath the Short White Coat: A Medical Student Reveals All 2Health News:Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today 2Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 2Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 3Health News:Annual screening with breast ultrasound or MRI could benefit some women 2
...spital which is to be built on the site of Birming...gnal. The plans for this new ?600m super hospital .../. It is funded by a private finance initiative. ...ble. The Treasury has also approved the schem...
...ying a drive for better hygiene at rural levels, t... its threats against panchayat leaders who fail to...s. Last year the state assembly had amended th...lush in their homes within a year of being elected...
...ts have discovered that watching television for an...167 calories thereby adding over than six kilogram...ve discovered that watching television for an hour...n the first to put an exact figure has been put on...
...ead of the NHS, Sir Ian Carruthers, has proposed c...million NHS deficit//. He proposes to unveil h...ony Blair. Sir Ian believes the ?10.3 billion spen... they could benefit have arisen. NHS had been ...
...s syndrome, a common running ailment, can be treat...g to Dr. Ronald Adler, chief, Division of Ultrasou...be used to accurately diagnose the ailment and rel...ed by the back of the shoe consistently rubbing ag...
...who was convicted of murdering Lin Russell and her...he publication of a report that probes the failure...ling spree. // The independent report by Robert..., Josie and her father, Shaun wants the report to ...
Other Medicine News:Health News:Madhya Pradesh To Concentrate On Better Rural Hygiene 2Health News:Watching TV Blamed for Weight Gain 2Health News:Proper Diagnosis Could Augment Speedy Recovery Of Haglund’s Syndrom 2
(Date:12/1/2009)...., Dec. 1 CeloNova BioSciences, In... medical devices and of specialty implants, today ..., founder and medical director of Baptist Cardiac ...iscuss the CATANIA(TM) Stent System with NanoThin ...lar Interventions Conference to be held at the Hot...
(Date:12/1/2009)... and TOKYO, Dec. 1 Galenea Corp. a... the further extension of their research and devel...tension increases the collaboration term to seven ...proximately $90 million. The companies have been ...of discovering and developing first-in-class thera...
(Date:12/1/2009)...., Dec. 1 SCOLR Pharma, ... 20, 2009 it licensed to Chrono Nutraceuticals LLC...l four extended release dietary supplements using ...rm. In addition, SCOLR granted Chrono rights to m...ited States on a nonexclusive basis. Chrono paid ...
Breaking Medicine Technology:Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3SCOLR Pharma, Inc. Licenses Dietary Supplements 2SCOLR Pharma, Inc. Licenses Dietary Supplements 3American Nurses Association Joins the National Healthcare Career Network 54285 1American Nurses Association Joins the National Healthcare Career Network 54285 2American Nurses Association Joins the National Healthcare Career Network 54285 3Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 1Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 2Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 3The tourist trap 9540 1
...ial New Front-Line Treatment ...Genzyme Corp.,(Nasdaq: GENZ ) reported preliminar...2 study examining the safety and effectiveness of ...ously untreated, older adult,patients with acute m...fit,from conventional "7+3" anthracycline plus cyt...
...CALS, INC. (Nasdaq: VION ) today announced that i... lead anticancer agent Cloretazine(R),(VNP40101M) ...yelogenous,leukemia (AML) had been presented at th...linical Oncology (ASCO(R)) in Chicago, Illinois., ...atients. The median,age of these patients was 73 y...
Other Medicine Technology:Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4
Fast-Cath™ Guiding Introducers
Lumenis 1000 Integrated Slit Lamp
Novus 30001
Selecta Trio Photocoagulator and SLT Combination Laser
Medicine Products: